Atorvastatin combined to interferon to verify the efficacy (ACTIVE) in relapsing-remitting active multiple sclerosis patients: A longitudinal controlled trial of combination therapy

Multiple Sclerosis

Volumn 16, Issue 4, 2010, Pages 450-454

  Lanzillo, Roberta ^a,b   Orefice, Giuseppe ^a   Quarantelli, Mario ^a,c   Rinaldi, Carlo ^a   Prinster, Anna ^c,d   Ventrella, Gianluca ^a   Spitaleri, Daniele ^e   Lus, Giacomo ^f   Vacca, Giovanni ^a   Carotenuto, Barbara ^a   Salvatore, Elena ^a   Brunetti, Arturo ^a   Tedeschi, Gioacchino ^b,f   Morra, Vincenzo Brescia ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Hermitage Capodimonte   (Italy)

^c CNR   (Italy)

^d IRCCS SDN   (Italy)

^e S G MOSCATI HOSPITAL   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Activity; Combination therapy; Interferon beta; Multiple sclerosis; Statin

Indexed keywords

ATORVASTATIN; BETA1A INTERFERON; GADOLINIUM; ANTIINFLAMMATORY AGENT; BETA INTERFERON; CONTRAST MEDIUM; DIAGNOSTIC AGENT; HEPTANOIC ACID DERIVATIVE; PYRROLE DERIVATIVE;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD ANALYSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; LONGITUDINAL STUDY; LOW DRUG DOSE; MALE; MONOTHERAPY; MULTIPLE SCLEROSIS; MUSCLE CRAMP; MYALGIA; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RELAPSE; RISK ASSESSMENT; SCREENING; SIDE EFFECT; SURVIVAL; TREATMENT DURATION; TREATMENT RESPONSE; CHI SQUARE DISTRIBUTION; DISABILITY; DRUG ADMINISTRATION; DRUG COMBINATION; HOSPITALIZATION; NONPARAMETRIC TEST; PREDICTION AND FORECASTING; TIME; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS; CHI-SQUARE DISTRIBUTION; CONTRAST MEDIA; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; INTERFERON-BETA; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PREDICTIVE VALUE OF TESTS; PYRROLES; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 77954688218     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509358909     Document Type: Article

References (14)

1. Baum H, Rothschild B. The incidence and prevalence of reported multiple sclerosis. Ann Neurol 1981;10:420-428.
2. Weinshenker B, Bass B, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112:133-146. (Pubitemid 19056478)
3. Aktas O, Waiczies S, Smorodchenko A, et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003;197:725-733.
4. Youssef S, Stuve O, Patarroyo JC, et al. The HMGCoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002;420:78-84.
5. Vollmer T, Key L, Durkalski V, et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004;363:1607-1608. (Pubitemid 38625664)
6. Birnbaum G, Cree B, Altafullah I, Zinser M, Reder AT. Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. Neurology 2008;71:1390-1395.
7. Paul F, Waiczies S, Wuerfel J, et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE 2008; Apr. 9: e1928.
8. Rudick RA, Pace A, Rani MR, et al. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology 2009;72:1989-1993.
9. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
10. Greenwood J, Walters CE, Pryce G, et al. Lovastatin inhibits brain endothelial cell Rho-mediated lymphocyte migration and attenuates experimental autoimmune encephalomyelitis. FASEB J 2003;17:905-907.
11. Neuhaus O, Strasser-Fuchs S, Fazekas F, et al. Statins as immunomodulators. Neurology 2002;59:990-997.
12. Miron V, Zehntner SP, Kuhlman T, et al. Statin therapy inhibits remyelination in the central nervous system. Am J Pathol 2009;174:1880-1890.
13. Sorensen PS, Frederiksen JL, Lycke L, et al. Does simvastatin antagonise the effect of interferon beta? Interim safety analysis of ongoing SIMCOMBIN study. ECTRIMS 2007, 11-14 October 2007, Prague, Czech Republic. Abstract 85.
14. Martinez-Yelamos S, Martinez-Yelamos A, Martin Ozaeta G, et al. Regression to the mean in multiple sclerosis. Mult Scler 2006;12:826-829.